Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim
Boehringer Ingelheim increases donation for emergency flood relief to EUR 1 million
Vyhledat
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Spiriva®
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Spiriva® Respimat®
An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Spiolto® Respimat®
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Striverdi® Respimat®
Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Combivent® Respimat®
A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.